^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CTLA4 overexpression

    i
    Other names: CTLA4, Cytotoxic T-Lymphocyte Associated Protein 4, Insulin-Dependent Diabetes Mellitus 12, Cytotoxic T-Lymphocyte Protein 4, Celiac Disease 3, CTLA-4, CD152, Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4, Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form, Cytotoxic T-Lymphocyte-Associated Serine Esterase-4, Cytotoxic T-Lymphocyte-Associated Antigen 4, CD152 Isoform, CD152 Antigen, CELIAC3, IDDM12, ALPS5, GRD4
    Entrez ID:
    1493
    Related biomarkers:
    Expression
    Mutation
    Others
    12ms
    Сytotoxic T lymphocyte-associated protein-4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas. (PubMed, Endocr Relat Cancer)
    Eight of 25 (32%) prolactinomas and 3 of 11 (27%) GH-adenomas had an H-score greater than 20, while no differences were seen for the other types. These novel data highlight the expression of an immune checkpoint such as CTLA4 on pituitary endocrine cells, a finding that could be exploited for therapeutical applications.
    Journal • IO biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    CTLA4 overexpression • CTLA4 expression • CTLA4 underexpression
    over1year
    Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming. (PubMed, Sci Rep)
    Priming the primary tumour with high-intensity (~ 60 bar) photoacoustic waves generated with nanosecond-pulsed lasers and light-to-pressure transducers improved the response of 4T1 tumours to PDT. Penetration-resistant tumours require a combination of approaches to respond to treatments: tumour priming to facilitate drug infiltration, PDT for a strong local effect and a change in immunogenicity, and immunotherapy for a systemic effect.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
    |
    CD80 (CD80 Molecule)
    |
    PD-L1 expression • PD-L1 overexpression • CTLA4 overexpression • CTLA4 expression • CTLA4 underexpression
    over1year
    Intracellular Ctla4 overexpression promotes melanoma progression and metastasis (AACR 2023)
    Proteomics analysis identified apoptosis to be a major affected pathway and we found that Ctla4 ectopic-expressing mouse melanoma cells (B2905-Ctla4-ee) were significantly resistant to doxorubicin-induced apoptosis as compared to empty vector (EV) controls...Interestingly, we also found that CTLA4 translocated to mitochondria, where it downregulated oxidative phosphorylation and increased glycolysis. These findings lead us to hypothesize that CTLA4 plays a significant role in regulating apoptosis and mitochondrial metabolic functions, leading to the promotion of melanoma progression and metastasis.
    IO biomarker
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • BIRC5 (Baculoviral IAP repeat containing 5) • RAC1 (Rac Family Small GTPase 1) • BNIP3L (BCL2 Interacting Protein 3 Like) • CDC42 (Cell Division Cycle 42)
    |
    BRAF mutation • NRAS mutation • CTLA4 overexpression • CTLA4 expression • CTLA4 underexpression
    |
    doxorubicin hydrochloride
    almost2years
    The Prognostic and Therapeutic Potential of CTLA-4 in Hematological Malignancies. (PubMed, Expert Opin Ther Targets)
    Also, it seems that certain CTLA-4 gene polymorphisms are efficient factors in the course of HMs. Future studies may broaden our knowledge regarding the role of CTLA-4 in HMs.
    Journal • IO biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    CTLA4 overexpression • CTLA4 expression • CTLA4 underexpression
    2years
    Integrated machine learning methods identify FNDC3B as a potential prognostic biomarker and correlated with immune infiltrates in glioma. (PubMed, Front Immunol)
    Moreover, expression of FNDC3B was significantly associated with infiltrating levels of several types of immune cells and most of their gene markers in glioma. This study demonstrated that FNDC3B may be involved in the occurrence and development of glioma and can be regarded as a promising prognostic and immunotherapeutic biomarker for the treatment of glioma.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • FN1 (Fibronectin 1)
    |
    PD-L1 expression • CTLA4 overexpression • HAVCR2 expression • CTLA4 expression
    over2years
    Immune checkpoint genes expression in breast carcinoma: correlation with clinicopathological features and patients survival (ECP 2022)
    Our data support that CTLA-4, PDCD1, CD274, and PDCD1LG2 are potential biomarkers of BC aggressiveness. Para-doxically, CTLA-4 stratified a subgroup of HER2-enriched patients with a better outcome.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • PD-L2 (Programmed Cell Death 1 Ligand 2) • PUM1 (Pumilio RNA Binding Family Member 1)
    |
    CD276 expression • CTLA4 overexpression • CTLA4 expression • CTLA4 underexpression
    almost3years
    Inflammation-Related Gene Signature: An Individualized Risk Prediction Model for Kidney Renal Clear Cell Carcinoma. (PubMed, J Oncol)
    Moreover, except for METTL3 and ALKBH5, the other m6A regulators decreased in the high-risk subgroup. In conclusion, a novel inflammation-related gene signature comprehensively constructed in the current study may help stratify patients with KIRC.
    Journal • Gene Signature • IO biomarker
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • ACVR2A (Activin A Receptor Type 2A) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • METTL3 (Methyltransferase Like 3)
    |
    CTLA4 overexpression • CTLA4 expression
    over3years
    Comprehensive Analysis of Tumor Microenvironment Identified Prognostic Immune-Related Gene Signature in Ovarian Cancer. (PubMed, Front Genet)
    Furthermore, the five-immune-related-gene-signature prognostic model (CCL18, CXCL13, HLA-DOB, HLA-DPB2, and TNFRSF17)-based high-risk and low-risk groups were significantly related to OC overall survival. Immune-related genes were the promising predictors of prognosis and survival, and the comprehensive landscape of tumor microenvironmental cells of OC has potential for therapeutic schedule monitoring.
    Journal • Tumor Mutational Burden • Gene Signature • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1) • TNFRSF17 (TNF Receptor Superfamily Member 17) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    PD-L1 overexpression • CTLA4 overexpression • CTLA4 expression